Preclinical Evaluation of the Safety and Immunological Action of Allogeneic ADSC-Collagen Scaffolds in the Treatment of Chronic Ischemic Cardiomyopathy

• Egile Nagusiak: Ascensión López-Díaz de Cerio (Egilea), Iñigo Perez-Estenaga (Egilea), Susana Inoges (Egilea), Gloria Abizanda (Egilea), Juan José Gavira (Egilea), Eduardo Larequi (Egilea), Enrique Andreu (Egilea), Saray Rodriguez (Egilea), Ana Gloria Gil (Egilea), Verónica Crisostomo (Egilea), Francisco Miguel Sanchez-Margallo (Egilea), Javier Bermejo (Egilea), Blanca Jauregui (Egilea), Lluis Quintana (Egilea), Francisco Fernández-Avilés (Egilea), Beatriz Pelacho (Egilea), Felipe Prósper (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The use of allogeneic adipose-derived mesenchymal stromal cells (alloADSCs) represents an attractive approach for treating myocardial infarction (MI). Furthermore, adding a natural support improves alloADSCs engraftment and survival in heart tissues, leading to a greater therapeutic effect. We aimed...